Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8+ T-cell response

Publication date: 8 June 2016
Source:Vaccine, Volume 34, Issue 27
Author(s): Delphine Knittel, Adeline Gadzinski, Stéphane Hua, Jordan Denizeau, Alexandra Savatier, Philippe de la Rochère, Jean-Claude Boulain, Sebastian Amigorena, Eliane Piaggio, Christine Sedlik, Michel Léonetti
Heparan sulfates (HS) are carbohydrate moieties of HS proteoglycans (HSPGs). They often represent alternative attachment points for proteins or microorganisms targeting receptors. HSPGs, which are ubiquitously expressed, thereby participate in numerous biological processes. We previously showed that MHC class II-restricted antigen presentation is increased when antigens are coupled to HS ligands, suggesting that HSPGs might contribute to adaptive immune responses. Here, we examined if HSPG targeting influences other aspects of immune responses. We found that coupling of an HS ligand to the antigen increases antigen presentation to CD4⁺ and CD8⁺ T-cells after antigen targeting to membrane immunoglobulins or to MHC-II molecules. Moreover, this increased stimulating capacity correlates with an enhanced CD8⁺ immune response in mice. Last, animals control more effectively the growth of Ova-expressing tumour cells when they are immunized with an Ova construct targeting HSPGs and MHC-II molecules. Our results indicate that ubiquitous molecules can influence both MHC class I- and MHC class II-restricted antigen presentation and behave as co-receptors during T-cell stimulation. Moreover, they suggest that tumour-antigens endowed with the ability to target both HSPGs and MHC-II molecules could be of value to increase CD8⁺ immune response and control tumour-growth, opening new perspectives for the design of highly immunogenic protein-based vaccines.



from #Medicine via ola Kala on Inoreader http://ift.tt/1U1i3BF
via IFTTT